PPAR-γ in the Cardiovascular System

Abstract EN

Peroxisome proliferator-activated receptor-γ (PPAR-γ), an essential transcriptional mediator of adipogenesis, lipid metabolism, insulin sensitivity, and glucose homeostasis, is increasingly recognized as a key player in inflammatory cells and in cardiovascular diseases (CVD) such as hypertension, cardiac hypertrophy, congestive heart failure, and atherosclerosis.

PPAR-γ agonists, the thiazolidinediones (TZDs), increase insulin sensitivity, lower blood glucose, decrease circulating free fatty acids and triglycerides, lower blood pressure, reduce inflammatory markers, and reduce atherosclerosis in insulin-resistant patients and animal models.

Human genetic studies on PPAR-γ have revealed that functional changes in this nuclear receptor are associated with CVD.

Recent controversial clinical studies raise the question of deleterious action of PPAR-γ agonists on the cardiovascular system.

These complex interactions of metabolic responsive factors and cardiovascular disease promise to be important areas of focus for the future.